GlycoMimetics files updated investor presentation for Crescent Biopharma merger

CRESCENT BIOPHARMA, INC.

Investor presentation for proposed merger with Crescent Biopharma updated as of January 2025.
Presentation furnished under Regulation FD and includes proxy solicitation materials for stockholder vote.
No new financial projections or merger consideration details disclosed in the filed exhibit.
Supplemental to prior proxy statement filed with the SEC on April 1, 2024.
Merger requires stockholder approval; no change to expected timeline communicated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.